Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Lymphoma, T-Cell, Cutaneous 2Vascular Malformations 1Surgical Wound Infection 1Pancreatic Neoplasms 1Pain 1Mycosis Fungoides 1Keratosis, Actinic 1High-grade Anal Intraepithelial Neoplasia 1Hemangioma, Capillary 1Hemangioma 1Head and Neck Neoplasms 1Dermatitis, Contact 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Lymphedema 1

Interventions

Gemcitabine 406Oxaliplatin 131Fluorouracil 125130-nm albumin-bound paclitaxel 108Capecitabine 100Albumin-Bound Paclitaxel 90Leucovorin 88Irinotecan 87Radiotherapy 76Radiosurgery 64Taxes 63Cisplatin 56Erlotinib Hydrochloride 44Drug Therapy 42folfirinox 40Magnetic Resonance Spectroscopy 39pembrolizumab 35Blood Specimen Collection 33S 1 (combination) 31Pancreaticoduodenectomy 31Docetaxel 31Nivolumab 30Bevacizumab 30Biopsy 26Surgical Procedures, Operative 25Cyclophosphamide 25irinotecan sucrosofate 24Specimen Handling 24Radiation 22Standard of Care 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pancreatic Neoplasms × Ointments × Clear all
NCT01593995 2014-11-04

EGF Ointment for Erlotinib Skin Lesion

Dong-A University Hospital

Phase 2 Completed
52 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡